Livingstone Fultang

Birmingham, ENG B152TT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial.

The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase 2 single-arm, open-label trial.

Journal: Journal of leukocyte biology

Published: December 12, 2025

PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults.

PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults.

Journal: Frontiers in oncology

Published: September 18, 2023

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment.

Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment.

Journal: Blood advances

Published: June 06, 2022

Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment.

Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment.

Journal: Cancer immunology, immunotherapy : CII

Published: February 18, 2022

G-CSF induces CD15+ CD14+ cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment.

G-CSF induces CD15+ CD14+ cells from granulocytes early in the physiological environment of pregnancy and the cancer immunosuppressive microenvironment.

Journal: Clinical & translational immunology

Published: November 09, 2021

Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.

Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.

Journal: Frontiers in oncology

Published: March 01, 2021

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.

Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.

Journal: Blood

Published: December 27, 2019

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers.

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers.

Journal: EBioMedicine

Published: June 04, 2019

Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.

Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.

Journal: International journal of cancer

Published: August 20, 2018

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Journal: Cancer research

Published: July 13, 2018

Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Journal: International journal of cancer

Published: November 02, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026